Asensus Surgical, Inc.

Thank you for standing by. This is the conference operator. Welcome to the Ascensus Third Quarter Financial and Operating Results conference call. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To join the question queue, you may press star then 1 on your telephone keypad. Should you need assistance during the conference call, you may signal an operator by pressing star and 0. I would now like to turn the conference over to Mark Klossner of Westwick Partners. Please go ahead.

Good afternoon, everyone, and thank you for joining us for the Ascensus Third Quarter 2021 Conference Call. On the call with me today are Anthony Fernando, President and Chief Executive Officer, and Shamiz Rampertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward-looking statements covered under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business, including any impact from the COVID-19 pandemic. The company undertakes no obligation to update the information provided on this call. For a discussion of risks and uncertainties associated with the Ascensus surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the 2020 Form 10-K, filed in March 2021, and the Form 10-Q, expected to be filed later today, and other filings we make with the SEC. During this call, we will also present certain non-GAAP financial information related to the adjusted net loss attributable to common stockholders and the adjusted net loss per common share attributable to common stockholders. Management believes that these non-GAAP financial measures taken in conjunction with U.S. GAAP financial measures provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP measures to compare our performance relative to forecast and strategic plans, to benchmark our performance externally against competitors, and for certain compensation decisions. Reconciliations from U.S. GAAP to non-GAAP results are presented in the tables accompanying our earnings release, which can be found in the investor relations section of our website. It is now my pleasure to turn the call over to Ascensus Surgical's President and Chief Executive Officer, Anthony Fernando.

Thanks, Bob. And thank you all for joining us today. On today's call, I will provide a brief summary of our recent accomplishments and then ask Shamice to review our financial performance, after which I will discuss our performance during the third quarter, as well as our priorities for the rest of 2021 before turning to Q&A. Starting with a review of our recent performance. Despite the headwinds associated with the recent COVID-19 Delta variant spike during the quarter, we made tremendous progress towards many of our 2021 goals since our last call. We signed lease agreements with three hospitals, and we sold one system, bringing the total number of new Sennheis program initiations thus far in 2021 to six. We made progress with our regulatory milestones receiving FDA 510 clearance for both the 5-millimeter articulating instruments and the expanded capabilities of the Intelligent Surgical Unit, or ISU, in July and September, respectively. We are incredibly happy with what we've accomplished so far, and we are excited to keep the momentum going in 2021. With that, I will turn the call over to Shamis for a financial update.